What question did this study set out to answer?

To study the impact of cancer therapies on DNA methylation patterns in survivors of hematologic malignancies.

December 8, 2025BloodOpen Access

Impact of cancer and therapy on the epigenetic landscapes of normal cells: Describing a novel biomarker in survivorship

View Full Paper

Ask AI

Bookmark

Authors

Observational cohort study shows DNA methylation changes in survival from hematologic cancers, indicating long-term epigenetic effects.

To study the impact of cancer therapies on DNA methylation patterns in survivors of hematologic malignancies.
Conducted an observational cohort study of blood methylation profiles in cancer survivors aged 30-50 years.
Analyzed cohorts of Hodgkin's Lymphoma, Acute Promyelocytic Leukemia, and Acute Myeloid Leukemia survivors, disease-free for over 5 years.
Assessed whole-genome methylation patterns using Illumina's Infinium MethylationEPIC v2.0 BeadChips.
Cancer survivor cohorts showed different methylation profiles compared to age-matched controls.
Average aberrant DNA methylation was higher: 2.34% in HL, 6.93% in APL, and 10.68% in AML survivors.
DunedinPACE analysis indicated significant epigenetic age acceleration in HL, APL, and AML survivors.

Kulkarni et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark